Synopsis: Divi’s Laboratories has recommended a dividend of ₹30 per equity share for FY2025-26, representing a payout of 1,500% on face value. The record date has been fixed as July 24, 2026, while the company continues to maintain a strong financial position supported by steady earnings growth, a debt-free balance sheet, and expansion into high-growth pharmaceutical segments.
Shares of Divi’s Laboratories Limited, with a market capitalization of Rs. 1,77,983.41 crore, were trading at Rs. 6,704.50, up 0.99% from the previous close of Rs. 6,638.50. The stock touched an intraday high of Rs. 6,713.00 and low of Rs. 6,625.00, and is currently trading at a P/E ratio of 68.63.
Divi’s Laboratories Limited has informed stock exchanges that its Board of Directors, at a meeting held on May 23, 2026, recommended a dividend of ₹30 per fully paid-up equity share of face value ₹2 each for the financial year ended March 31, 2026. The proposed dividend represents a payout of 1,500% on face value and remains subject to shareholder approval at the company’s 36th Annual General Meeting (AGM), scheduled for August 10, 2026.
If approved, the dividend will be paid on or after August 14, 2026. The company has fixed July 24, 2026, as the record date for determining shareholders eligible to receive the dividend.
Alongside the dividend announcement, Divi’s Laboratories has issued detailed instructions regarding tax deducted at source (TDS) applicable to dividend income. Resident shareholders with a valid PAN linked to Aadhaar will be subject to TDS at 10%, while those with an inoperative or invalid PAN may face deduction at a higher rate of 20%. Resident individuals whose total dividend income does not exceed ₹10,000 may qualify for exemption, while certain institutional investors such as insurance companies, mutual funds, Alternative Investment Funds (AIFs), and NPS Trusts can claim exemption by submitting the prescribed declarations and supporting documents.
For non-resident shareholders, dividend income will generally attract withholding tax at 20% along with applicable surcharge and cess. However, eligible investors can seek lower tax rates under applicable Double Tax Avoidance Agreements (DTAAs) by submitting the required documentation, including a valid Tax Residency Certificate and Form 41. The company has requested shareholders to upload all relevant tax documents through KFinTech’s online portal on or before July 24, 2026, as documents submitted after the deadline will not be considered for TDS determination.
The dividend recommendation comes against the backdrop of another year of healthy financial performance. For the fourth quarter of FY26, Divi’s Laboratories reported a consolidated net profit of ₹751 crore, up 13.4% from ₹662 crore in the corresponding quarter of the previous year. Revenue from operations rose 9.5% year-on-year to ₹2,831 crore, reflecting continued demand across its pharmaceutical manufacturing portfolio.
For the full financial year FY26, the company reported revenue of ₹10,560 crore and net profit of ₹2,568 crore, representing annual growth of 12.8% and 17.2%, respectively. The strong earnings performance has provided a solid foundation for the company’s continued shareholder payout while maintaining significant investments in future growth initiatives.
Although the dividend translates into a yield of around 0.45% based on the current share price of approximately ₹6,638, slightly below the pharmaceutical industry’s average yield of about 0.6%, the payout remains well supported by earnings. The dividend represents an estimated payout ratio of around 31% to 39%, indicating that the company continues to retain a substantial portion of profits for expansion and capital expenditure. Divi’s also stands out for its consistency, having maintained uninterrupted dividend payments for nearly two decades.
Looking ahead, investors are closely watching the company’s growth initiatives for FY27 and beyond. A major focus remains the development and scaling of its Kakinada Unit 3 facility, where the company is undertaking a multi-year capital expenditure program estimated at ₹1,500 crore to ₹2,000 crore. The facility is expected to strengthen Divi’s capabilities in high-complexity pharmaceutical manufacturing and support long-term growth.
The company is also positioning itself to capitalize on emerging opportunities in the rapidly expanding GLP-1 agonist market, which includes obesity and weight-loss therapies, as well as the contrast media segment used in diagnostic imaging. These areas are expected to become important growth drivers over the next few years and could contribute meaningfully to revenue expansion through 2027.
While EBITDA margins moderated to around 33% during the fourth quarter due to higher raw material and freight costs, market analysts expect margins to stabilize as production volumes increase and capacity utilization improves across newer facilities.
From a market perspective, Divi’s Laboratories continues to be viewed as one of the pharmaceutical sector’s defensive large-cap plays. Its debt-free balance sheet, strong cash generation, and consistent profitability have helped the stock attract investors during periods of broader market volatility. Over the past 52 weeks, the stock has traded between a low of ₹5,636.50 and a high of ₹7,071.50.
Divi’s Laboratories has built a reputation as one of India’s most consistent dividend-paying pharmaceutical companies, and the FY26 dividend recommendation reinforces its shareholder-friendly capital allocation approach while balancing investments for future growth.
Company Overview
Headquartered in Hyderabad, Divi’s Laboratories is one of India’s leading Active Pharmaceutical Ingredient (API) manufacturers and a major global supplier of generic APIs and custom synthesis intermediates. The company operates advanced manufacturing facilities in Telangana, serves customers across regulated global markets including North America, Europe, and Japan, and is a constituent of the Nifty 50 index.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
